JP2009532360A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532360A5
JP2009532360A5 JP2009503047A JP2009503047A JP2009532360A5 JP 2009532360 A5 JP2009532360 A5 JP 2009532360A5 JP 2009503047 A JP2009503047 A JP 2009503047A JP 2009503047 A JP2009503047 A JP 2009503047A JP 2009532360 A5 JP2009532360 A5 JP 2009532360A5
Authority
JP
Japan
Prior art keywords
skin
compound
carrier
suspensions
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009503047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532360A (ja
JP5253374B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/007989 external-priority patent/WO2007120454A1/en
Publication of JP2009532360A publication Critical patent/JP2009532360A/ja
Publication of JP2009532360A5 publication Critical patent/JP2009532360A5/ja
Application granted granted Critical
Publication of JP5253374B2 publication Critical patent/JP5253374B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009503047A 2006-03-30 2007-03-30 カンナビノイド受容体1活性の阻害剤としてのアゾロピリミジン類 Expired - Fee Related JP5253374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78831006P 2006-03-30 2006-03-30
US60/788,310 2006-03-30
PCT/US2007/007989 WO2007120454A1 (en) 2006-03-30 2007-03-30 Azolopyrimidines as inhibitors of cannabinoid 1 activity

Publications (3)

Publication Number Publication Date
JP2009532360A JP2009532360A (ja) 2009-09-10
JP2009532360A5 true JP2009532360A5 (cg-RX-API-DMAC7.html) 2010-05-06
JP5253374B2 JP5253374B2 (ja) 2013-07-31

Family

ID=38294112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503047A Expired - Fee Related JP5253374B2 (ja) 2006-03-30 2007-03-30 カンナビノイド受容体1活性の阻害剤としてのアゾロピリミジン類

Country Status (21)

Country Link
US (1) US8722691B2 (cg-RX-API-DMAC7.html)
EP (1) EP1999132B1 (cg-RX-API-DMAC7.html)
JP (1) JP5253374B2 (cg-RX-API-DMAC7.html)
KR (1) KR100997601B1 (cg-RX-API-DMAC7.html)
CN (1) CN101454327A (cg-RX-API-DMAC7.html)
AU (1) AU2007239033B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710107A2 (cg-RX-API-DMAC7.html)
CA (1) CA2645967C (cg-RX-API-DMAC7.html)
CR (1) CR10309A (cg-RX-API-DMAC7.html)
EC (1) ECSP088852A (cg-RX-API-DMAC7.html)
ES (1) ES2388881T3 (cg-RX-API-DMAC7.html)
GT (1) GT200800198A (cg-RX-API-DMAC7.html)
MA (1) MA30339B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012400A (cg-RX-API-DMAC7.html)
NO (1) NO20084489L (cg-RX-API-DMAC7.html)
PL (1) PL1999132T3 (cg-RX-API-DMAC7.html)
PT (1) PT1999132E (cg-RX-API-DMAC7.html)
RU (1) RU2424242C2 (cg-RX-API-DMAC7.html)
TN (1) TNSN08373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007120454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807862B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8487099B2 (en) 2007-11-05 2013-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
WO2009076352A1 (en) * 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
BR112015027394A8 (pt) * 2013-05-02 2018-01-30 Hoffmann La Roche derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2
CR20220661A (es) * 2016-06-23 2023-02-21 Hoffmann La Roche NUEVOS DERIVADOS DE [1,2,3]TRIAZOLO[4,5-D]PIRIMIDINA (Divisional 2018-0615)
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
TWI800498B (zh) * 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
KR20220059480A (ko) 2019-08-06 2022-05-10 인사이트 코포레이션 고체 형태의 hpk1 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2005049615A1 (en) 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
WO2005061505A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof
TW200528455A (en) 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
AR051596A1 (es) * 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios

Similar Documents

Publication Publication Date Title
MA71659A (fr) Compositions pour l'administration de molécules de charge utile à l'épithélium des voies respiratoires
JP2007504159A5 (cg-RX-API-DMAC7.html)
JP2024516371A5 (cg-RX-API-DMAC7.html)
JP2007501251A5 (cg-RX-API-DMAC7.html)
JP2009102342A5 (cg-RX-API-DMAC7.html)
JP2010077141A5 (cg-RX-API-DMAC7.html)
RU2361593C3 (ru) Комбинация азеластина и стероидов
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
BRPI0418270A (pt) métodos de tratamento e de controle, de tratamento ou prevenção, de controle de um distúrbio do sistema nervoso central, e para reduzir ou evitar um efeito adverso, e, composição farmacêutica
ECSP066807A (es) Formulaciones galénicas de compuestos orgánicos
JP2010530376A5 (cg-RX-API-DMAC7.html)
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
JP2014530881A5 (cg-RX-API-DMAC7.html)
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
ES2219342T3 (es) Nuevo uso de 1-(5-cianoindol-3-il)butil)-4-(2-carbamoilbenzofuran-5-il)-piperazina y sus sales fisiologicamente aceptables para el tratamiento de trastornos bipolares y mania.
WO2009044883A1 (ja) モルヒナン誘導体またはその薬理学的に許容される酸付加塩を有効成分とする皮膚性状改善治療薬
JP2013508282A5 (cg-RX-API-DMAC7.html)
JP2009521473A5 (cg-RX-API-DMAC7.html)
WO2011047048A1 (en) Combination therapy treatment for viral infections
JP2024544538A5 (cg-RX-API-DMAC7.html)
BRPI0919526B8 (pt) derivado de ciclo-hexano, e, produto farmacêutico
JP2008513510A5 (cg-RX-API-DMAC7.html)
CO6351721A2 (es) Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio
JP2012508256A5 (cg-RX-API-DMAC7.html)